Using radiofrequency to reduce liver cancer recurrence after surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the use of radiofrequency devices during liver surgery to improve hemostasis and potentially reduce local recurrence of liver cancer. It focuses on the application of additional margin coagulation after tumor resection, particularly in cases where the surgical margins are questionable. The study aims to determine whether this technique can enhance overall survival rates and minimize the risk of recurrence, despite concerns about liver ischemia. Participants will be monitored for outcomes related to their liver cancer treatment.

Why it matters

Who can join: the full rules

Inclusion criteria:

1. Written informed consent granted prior to the initiation of the surgical procedure, given with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.
2. 18 year of age or older.
3. WHO performance scale 0-2
4. Consecutive patients (both sexes equally distributed) suffering from CRLM confirmed either by abdominal CT, abdominal MRI or/and by histologic-cytological evaluation or patients suffering from HCC.
5. Any previous chemotherapy regime is permitted.
6. ASA score 1 to 3.

Exclusion criteria:

1. Previous or concurrent cancer that is distinct from one primary tumor of which the Liver metastasis comes from EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis \& T1).
2. Any cancer curatively treated \> 3 years prior to enrollment is permitted.
3. ASA 4.
4. Non-resectable extrahepatic metastases.
5. Liver metastasis from other origin apart from colorectal.
6. Bening primary tumor of the liver.
7. Pregnant woman.
8. Participation in another clinical trial.

Where it's running

• Hospital del Mar Research Institute
  Barcelona, Spain Recruiting

Study contacts

• Principal investigator: Patricia Sánchez Velazquez, MD PhD FEBS — Hospital del Mar
• Study coordinator: Carlos fuste, MD PhD
• Email: cfuste@imim.es
• Phone: 0034 932483207

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer

  This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.

  Recruiting at 2 sites Phase 3 BeOne Medicines · South Brisbane, Queensland and 1 other locations · NCT07836530

• Protoacoustic Imaging to See Radiation Delivery in Proton Therapy

  This study tests radioacoustic imaging with ultrasound to help doctors see where proton therapy is delivering radiation for liver and prostate cancer patients.

  Recruiting University of Oklahoma · Oklahoma City, Oklahoma · NCT07832617

• YMN-136 vaccine for advanced liver, biliary tract, and pancreatic cancers

  A first-in-human dose-escalation study tests whether the YMN-136 vaccine is safe and tolerable for adults with unresectable advanced liver, biliary tract, or pancreatic cancers who have progressed on standard therapies or cannot receive them.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07763301

• DRAGON: International registry for patients who had combined portal and hepatic vein embolization before liver surgery

  This registry collects data on patients who had PVE/HVE before liver resection to see if it helps liver regeneration and what factors relate to outcomes.

  Recruiting at 30 sites Maastricht University Medical Center · Chicago, Illinois and 30 other locations · NCT07717437

• Precision navigation to boost cancer screening participation in high-risk communities

  This study tests whether a personalized navigation program helps adults aged 45–74 in Chinese communities who are at high risk for several cancers to complete recommended free cancer screenings.

  Recruiting at 3 sites Hunan Cancer Hospital · Huaihua, Hunan and 2 other locations · NCT07676383

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.